& The Motley Fool
Good day, 360!
Here are some of our top movers today. Be the best prepared trader on the Street!
Reminder: Get JW’s next FOUR picks of the Week for just $29. Offer Expires in Just…
FOCUS LIST🔎
TRAW – Up over 100% in the pre-market after announcing progress in developing Tivoxavir Marboxil for H5N1 Bird Flu
RAPT – Up over 40% in pre after announcing exclusive license agreement with Shanghai Jemincare Pharmaceutical for novel long-acting anti-IgE antibody
PRZO – Up over 20% in pre after announcing it had secured major Australian order for drone safety systems, strengthening industry leadership
*sponsored by CompareCredit
2 Cards Charging 0% Interest Until 2026
Paying down your credit card balance can be tough with the majority of your payment going to interest. Avoid interest charges for up to 18 months with these cards.
HOTLIST🔥
TRAW – Up over 100% in the pre-market after announcing progress in developing Tivoxavir Marboxil for H5N1 Bird Flu
Traws Pharma Inc. (TRAW) is a clinical stage biopharmaceutical company that focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer.
In the pre-market this morning, the company announced progress in the development of its investigational one-dose influenza (flu) investigational therapy, tivoxavir marboxil for treatment of H5N1 bird flu.
Highlights include:
Investigational agent in development for treatment or prevention of H5N1 Bird Flu
Phase 1 dosing completed in healthy volunteers
Potent inhibition of drug-resistant and bird flu viruses in vitro
In vivo study in mice, with H5N1 isolated from an infected dairy worker, showed potent protection and suppression of virus replication in lungs
Shares of TRAW traded up over 100% in the pre-market in reaction to the news.
The $9.70 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $10.70, $12.20, $13.50 and then the pre-market high at $15.89.
Below $9.70 targets to the downside are $9, $8, $7.50, $6 and then a gap fill at $5.02.
RAPT – Up over 40% in pre after announcing exclusive license agreement with Shanghai Jemincare Pharmaceutical for novel long-acting anti-IgE antibody
RAPT Therapeutics Inc. (RAPT) is a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States.
In the pre-market this morning, the company announced it has entered into an exclusive license agreement with Shanghai Jemincare Pharmaceutical for JYB1904 (RAPT designation RPT904), a clinical-stage, half-life extended anti-immunoglobulin E (IgE) monoclonal antibody.
Highlights of the transaction include:
– RAPT obtains worldwide rights excluding China –
– Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on future sales –
– Jemincare is currently conducting Phase 2 trials in asthma and chronic spontaneous urticaria in China –
Shares of RAPT traded up over 40% in the pre-market in reaction to the news.
The $1.40 area acted as resistance in the pre-market and will be an important level to watch.
Above it, targets to the upside are $1.60, $1.75 and then the pre-market high at $1.97.
Below $1.40, targets to the downside are $1.26, $1.16, $1 and then a gap fill at $0.8254.
*sponsored by The Motley Fool
Smart Money, Smart Machines
Dubbed “the rocket fuel of AI” by Wired, this innovation is causing a stir on Wall Street. With projections hitting $80 trillion – that’s 41 Amazons – the potential is huge. But here’s the deal: sharp investors who are ahead of the game have the opportunity to invest in a technology poised for domination. Thanks to The Motley Fool, you can access the full story in this exclusive report.
PRZO – Up over 20% in pre after PR that it had previously secured major Australian order for drone safety systems, strengthening industry leadership
ParaZero Technologies Ltd. (PRZO) is an aerospace company that designs, develops, manufactures, distributes, and sells autonomous parachute safety systems for commercial drones in the United States, Israel, Canada, Europe, and internationally.
In the pre-market this morning, the company released a press release stating that it had previously announced that it received an order for its SafeAir™ systems from a significant distributor specializing in drones and drone technology in Australia.
This order, which was announced earlier this month, highlights ParaZero’s accelerating growth in the Australian drone market, fuelled by its recent regulatory approvals and strategic collaborations. As the adoption of drones expands across industries, ParaZero’s cutting-edge solutions reflect its commitment to set and advance the standards for drone safety, empowering operators to meet the highest safety standards while advancing innovation.
Shares of PRZO traded up over 20% in the pre-market in reaction to the press release.
The $1.93 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $2.05, $2.20, $2.30 and then the pre-market high at $2.36. Beyond that, $2.44 and $2.77 come into play.
Below $1.93 there is a gap to fill at $1.76, with $1.53 below that.
MARKET NEWS 📰
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
*Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
Related Articles:
